Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Biogen (BIIB) PT Raised to $377 at BMO Capital Following 'Deep Dive on Aducanumab, More Confident on Phase 3 Outcome'
September 13, 2017 9:48 AM EDTBMO Capital raised its price target on Biogen (NASDAQ: BIIB) to $377.00 (from $328.00) while maintaining a Market Perform rating, following a review of aducanumab.
Analyst M. Ian Somaiya notes a positive outlook follow a detailed review of aducanumab, suggesting the analysis points to... More
